|
Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. |
|
|
Employment - Moffitt Cancer Center |
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; AstraZeneca; Autolus; BeiGene; Bristol-Myers Squibb; Century Therapeutics; Deciphera; Jazz Pharmaceuticals; Kite/Gilead; Lilly; Novartis; Pfizer; Precision BioSciences; Takeda |
Research Funding - Jazz Pharmaceuticals; Kite/Gilead; SERVIER |
Travel, Accommodations, Expenses - Kite/Gilead |
Other Relationship - DSMB: Pepromene Bio |
|
|
Employment - Real Chemistry |
Stock and Other Ownership Interests - Real Chemistry |
|
|
Employment - Real Chemistry |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - BeiGene |
Research Funding - BeiGene |
|
|
|
Stock and Other Ownership Interests - BeiGene |